Fut, nem toboroz2. fázis
Efficacy and tolerability of the combination of anifrolumab (300 mg IV) and phototherapy versus phototherapy in adults with progressive vitiligo
A legfontosabb adatok
- Ki végzi
- Centre Hospitalier Universitaire De Bordeaux
- Hol
- Franciaország5 helyszín, 1 országbanVálassz országot a helyszínekhez
- Állapot
- Fut, nem toboroz
- Fázis
- 2. fázis
- Résztvevők
- 48 fő, tervezett
- Kezdés
- 2023. nov. 27.
- Várható befejezés
- 2027. jún. 30.
- A vizsgálat típusa
- Beavatkozással járó
- A regiszteradat frissítve
- 2026. január 13.
Ki vehet részt
- Életkor
- 18 év felett
- Nem
- Nők és férfiak
- Egészséges önkéntesek
- Nem vehetnek részt
A regiszter feltételei, szó szerint
Mind a 16 feltétel megnézéseKevesebb
Ki vehet részt
- Subject male or female aged ≥ 18 years and ≤ 65 years
- Subject with body weight > or = 40kg
- Diagnosis of non-segmental (symmetrical) vitiligo with a body surface area involved >5% excluding hands and feet
- Active non-segmental vitiligo is defined by: • Non-segmental vitiligo with new patches or extension of old lesions during the last 6 months AND • Presence of hypochromic aspect under Wood’s lamp examination and/or perifollicular hypopigmentation under Wood’s lamp examination
- Able to read, understand, and give documented (electronic or paper signature) informed consent
- Affiliated or beneficiary of the French Social Security
- Agree to discontinue the use of the following excluded medications/treatments for at least 4 weeks prior to randomization (Visit 2): phototherapy
- Agree to discontinue the use of the following excluded medications/treatments for at least 4 weeks prior to randomization and throughout the study: systemic steroids, methotrexate, cyclosporine, mycophenolate mofetil, azathioprine
- Agree to discontinue the use of the following excluded medications for at least 2 weeks prior to randomization and throughout the study: • TCS or topical immune modulators (e.g., tacrolimus or pimecrolimus) • Topical phosphodiesterase type 4 (PDE-4) inhibitor (crisaborole) • Topical JAK inhibitor (e.g., tofacitinib or ruxolitinib) and/or any other investigational topical treatments
Ki nem vehet részt
- Are currently experiencing or have a history of other concomitant skin conditions (e.g., psoriasis or lupus erythematosus) that would interfere with evaluations of the effect of study medication on vitiligo
- Patients who are currently experiencing a skin infection that requires treatment, or who are currently being treated, with topical or systemic antibiotics. Note: Patients may not be rescreened until at least 4 weeks after the date of their previous screen failure and at least 2 weeks after resolution of the infection
- Have any serious concomitant illness that is anticipated to require the use of systemic corticosteroids or otherwise interfere with study participation or require active frequent monitoring (e.g., unstable chronic asthma)
- Current alcohol, drug, or chemical abuse
- Patients with history of basal cell or squamous epithelial skin cancer or melanoma
- Presence of significant uncontrolled neuropsychiatric disorder, are clinically judged by the investigator to be at risk for suicide
- Segmental or mixed vitiligo
Hol van ez a vizsgálat?
Egy országban van helyszíne. Válassz országot, hogy lásd a helyszíneket.
A vizsgálatról
Mit akar kideríteni a vizsgálat
To evaluate the efficacy of the combination of anifrolumab intravenous (IV) every four weeks + UVB TL01 (twice a week) by the evaluation of the percentage of skin repigmentation after 36 weeks of treatment using the VASI score in the experimental group receiving anifrolumab + UVB TL01.
Adatok és források
- Regiszteradat
- Szerepel a ClinicalTrials.gov-on és az EU hivatalos vizsgálati nyilvántartásában (CTIS).
- Hivatalos cím
- Efficacy and tolerance of the association of ANIFROLUMAB (300mg) IV every four weeks and phototherapy versus phototherapy in adults with progressive vitiligo: a randomized double blind prospective, non comparative Proof of Concept phase II study - VITANI
- A regiszteradat frissítve
- 2026. január 13.